{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:37:45Z","timestamp":1787161065958,"version":"build-2736575974"},"reference-count":91,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T00:00:00Z","timestamp":1729382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000046","name":"National Research Council Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.vaccine.2024.126463","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T06:21:30Z","timestamp":1730355690000},"page":"126463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["SARS-CoV-2 spike-based virus-like particles incorporate influenza H1\/N1 antigens and induce dual immunity in mice"],"prefix":"10.1016","volume":"42","author":[{"given":"Zalma V.","family":"Sanchez-Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio P.","family":"Alpuche-Lazcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Stuible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Akache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler M.","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Deschatelets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Dudani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"McCluskie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahudin","family":"Hrapovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Blouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Schuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Young","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Durocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126463_bb0005","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.126463_bb0010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/s12879-017-2716-y","article-title":"Variation in loss of immunity shapes influenza epidemics and the impact of vaccination","volume":"17","author":"Woolthuis","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126463_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.02.059","article-title":"Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: a systematic review, meta-analysis and meta-regression of test-negative design studies","author":"Guo","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126463_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009997","article-title":"Clinical and virological impact of single and dual infections with influenza a (H1N1) and SARS-CoV-2 in adult inpatients","volume":"15","author":"Zheng","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.126463_bb0025","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01873-21","article-title":"Coinfection with SARS-CoV-2 and influenza a virus increases disease severity and impairs neutralizing antibody and CD4+ T cell responses","volume":"96","author":"Kim","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)00383-X","article-title":"SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses","author":"Swets","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2024.126463_bb0035","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: a phase 2, randomised, open-label study","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2024.126463_bb0040","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/S0140-6736(21)02329-1","article-title":"Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial","volume":"398","author":"Lazarus","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.126463_bb0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2024.126463_bb0050","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/s41591-023-02282-y","article-title":"Determinants of COVID-19 vaccine fatigue","volume":"29","author":"Stamm","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.126463_bb0055","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1080\/14760584.2022.2117692","article-title":"Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza","volume":"21","author":"Stepanova","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.126463_bb0060","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01337-22","article-title":"A recombinant VSV-based bivalent vaccine effectively protects against both SARS-CoV-2 and influenza a virus infection","volume":"96","author":"Ao","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0065","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01578-21","article-title":"A single vaccine protects against SARS-CoV-2 and influenza virus in mice","volume":"96","author":"Cao","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0070","doi-asserted-by":"crossref","first-page":"2231573","DOI":"10.1080\/22221751.2023.2231573","article-title":"Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD","volume":"12","author":"Li","year":"2023","journal-title":"Emerging Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.126463_bb0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-022-00478-w","article-title":"Rational development of a combined mRNA vaccine against COVID-19 and influenza","volume":"7","author":"Ye","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.126463_bb0080","author":"Moderna"},{"key":"10.1016\/j.vaccine.2024.126463_bb0085","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.vaccine.2024.126463_bb0090","series-title":"Gardasil","volume":"9","author":"U.S. Food and drug administration","year":"2014"},{"key":"10.1016\/j.vaccine.2024.126463_bb0095","author":"European Medicines Agency"},{"key":"10.1016\/j.vaccine.2024.126463_bb0100","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/bit.26890","article-title":"Synthetic biology for bioengineering virus-like particle vaccines","volume":"116","author":"Charlton Hume","year":"2019","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2024.126463_bb0105","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fimmu.2020.01100","article-title":"Interaction between virus-like particles (VLPs) and pattern recognition receptors (PRRs) from dendritic cells (DCs): toward better engineering of VLPs","volume":"11","author":"Zepeda-Cervantes","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0110","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.vaccine.2024.03.034","article-title":"CHO cells for virus-like particle and subunit vaccine manufacturing","volume":"42","author":"Sanchez-Martinez","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126463_bb0115","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/all.15091","article-title":"Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection","volume":"77","author":"Yilmaz","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.vaccine.2024.126463_bb0120","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3390\/vaccines10121997","article-title":"Immunogenicity and efficacy of monovalent and bivalent formulations of a virus-like particle vaccine against SARS-CoV-2","volume":"10","author":"Resch","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2024.126463_bb0125","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2021.07.034","article-title":"An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity","volume":"39","author":"Fluckiger","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126463_bb0130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.vaccine.2023.11.048","article-title":"Production, purification and immunogenicity of gag virus-like particles carrying SARS-CoV-2 components","volume":"42","author":"Gashti","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126463_bb0135","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3390\/vaccines11111641","article-title":"Gag virus-like particles functionalized with SARS-CoV-2 variants: generation, characterization and recognition by COVID-19 convalescent patients&rsquo","volume":"11","author":"Boix-Besora","year":"2023","journal-title":"Sera Vaccines"},{"key":"10.1016\/j.vaccine.2024.126463_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015559","article-title":"Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza","volume":"5","author":"Landry","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2024.126463_bb0145","doi-asserted-by":"crossref","first-page":"10945","DOI":"10.1128\/JVI.05406-11","article-title":"H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans","volume":"85","author":"Khurana","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0150","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.1016\/j.vaccine.2011.07.099","article-title":"Safety and immunogenicity of a virus-like particle pandemic influenza a (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico","volume":"29","author":"L\u00f3pez-Mac\u00edas","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126463_bb0155","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clim.2016.03.008","article-title":"A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults","volume":"168","author":"Pillet","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0160","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1016\/j.vaccine.2015.09.065","article-title":"Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets","volume":"33","author":"Pillet","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126463_bb0165","series-title":"Advances in Glycobiotechnology","first-page":"319","article-title":"Impact of protein glycosylation on the Design of Viral Vaccines","author":"Sch\u00f6n","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126463_bb0170","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/pmic.201100474","article-title":"Comparative characterization of the glycosylation profiles of an influenza hemagglutinin produced in plant and insect hosts","volume":"12","author":"Zhang","year":"2012","journal-title":"Proteomics"},{"key":"10.1016\/j.vaccine.2024.126463_bb0175","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(20)32014-6","article-title":"Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (\u226565 years): two multicentre, randomised phase 3 trials","volume":"396","author":"Ward","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.126463_bb0180","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1016\/j.vaccine.2019.09.057","article-title":"Influenza a and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies","volume":"37","author":"Buffin","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126463_bb0185","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s43856-023-00340-7","article-title":"Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster ovary cells","volume":"3","author":"Alpuche-Lazcano","year":"2023","journal-title":"Commun Med"},{"key":"10.1016\/j.vaccine.2024.126463_bb0190","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/bit.28387","article-title":"A CHO stable pool production platform for rapid clinical development of trimeric SARS-CoV-2 spike subunit vaccine antigens","volume":"120","author":"Joubert","year":"2023","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2024.126463_bb0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbiotec.2020.12.005","article-title":"Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells","volume":"326","author":"Stuible","year":"2021","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069127","article-title":"The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters","volume":"8","author":"de Wit","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2024.126463_bb0205","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s42003-022-03866-z","article-title":"Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models","volume":"5","author":"Rossotti","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0210","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1007\/s00216-022-04000-y","article-title":"Characterization of a SARS-CoV-2 spike protein reference material","volume":"414","author":"Stocks","year":"2022","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.vaccine.2024.126463_bb0215","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jbiotec.2019.10.021","article-title":"Production of \u03b12,6-sialylated and non-fucosylated recombinant alpha-1-antitrypsin in CHO cells","volume":"307","author":"Lalonde","year":"2020","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0220","series-title":"Vaccine design: Methods and protocols, volume 3 resources for vaccine development","first-page":"255","article-title":"Generation of a liposomal vaccine adjuvant based on sulfated S-Lactosylarchaeol (SLA) glycolipids","author":"Akache","year":"2022"},{"key":"10.1016\/j.vaccine.2024.126463_bb0225","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2019.02.041","article-title":"A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations","volume":"561","author":"Jia","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2024.126463_bb0230","doi-asserted-by":"crossref","first-page":"21849","DOI":"10.1038\/s41598-021-01363-7","article-title":"Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant","volume":"11","author":"Akache","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.126463_bb0235","series-title":"Vaccine delivery technology: Methods and protocols","first-page":"537","article-title":"Measurement of antigen-specific IgG titers by direct ELISA","author":"Akache","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126463_bb0240","first-page":"14","article-title":"Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 omicron variant of concern","author":"Renner","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0245","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41541-022-00540-7","article-title":"Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern","volume":"7","author":"Akache","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.126463_bb0250","series-title":"Vaccine delivery technology: Methods and protocols","first-page":"525","article-title":"The quantification of antigen-specific T cells by IFN-\u03b3 ELISpot","author":"Akache","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126463_bb0255","doi-asserted-by":"crossref","DOI":"10.3791\/55833","article-title":"An optimized Hemagglutination inhibition (HI) assay to quantify influenza-specific antibody titers","author":"Kaufmann","year":"2017","journal-title":"J Vis Exp"},{"key":"10.1016\/j.vaccine.2024.126463_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.997875","article-title":"How promising are HIV-1-based virus-like particles for medical applications","volume":"12","author":"Martins","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0265","series-title":"Medicinal protein engineering","first-page":"205","article-title":"Construction of novel vaccines on the basis of the virus-like particles: Hepatitis B virus proteins as vaccine carriers","author":"Pumpens","year":"2008"},{"key":"10.1016\/j.vaccine.2024.126463_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.str.2022.02.014","article-title":"Quantitative structural analysis of influenza virus by cryo-electron tomography and convolutional neural networks","volume":"30","author":"Huang","year":"2022","journal-title":"Structure"},{"key":"10.1016\/j.vaccine.2024.126463_bb0275","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1038\/s41598-021-82852-7","article-title":"Morphometry of SARS-CoV and SARS-CoV-2 particles in ultrathin plastic sections of infected Vero cell cultures","volume":"11","author":"Laue","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.126463_bb0280","article-title":"Viral architecture of SARS-CoV-2 with post-fusion spike revealed by cryo-EM","author":"Liu","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2024.126463_bb0285","series-title":"Vaccine design: Methods and protocols, volume 3 resources for vaccine development","first-page":"179","article-title":"Adjuvants: Engineering protective immune responses in human and veterinary vaccines","author":"Akache","year":"2022"},{"key":"10.1016\/j.vaccine.2024.126463_bb0290","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1016\/j.vaccine.2019.07.010","article-title":"Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization","volume":"37","author":"Stark","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126463_bb0295","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.1038\/s41598-022-13819-5","article-title":"Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters","volume":"12","author":"Stark","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.126463_bb0300","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1038\/s41598-024-54421-1","article-title":"Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19\/influenza vaccine","volume":"14","author":"Handabile","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.126463_bb0305","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.126463_bb0310","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0168-1702(85)90060-7","article-title":"Sialic acid is incorporated into influenza hemagglutinin glycoproteins in the absence of viral neuraminidase","volume":"2","author":"Basak","year":"1985","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2024.126463_bb0315","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1348-0421.2004.tb03619.x","article-title":"Stimulation of phagocytosis of influenza virus-infected cells through surface Desialylation of macrophages by viral neuraminidase","volume":"48","author":"Watanabe","year":"2004","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0320","first-page":"4","article-title":"Dendritic cells: a spot on sialic acid","author":"Crespo","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0325","author":"BioNTech"},{"key":"10.1016\/j.vaccine.2024.126463_bb0330","author":"Moderna"},{"key":"10.1016\/j.vaccine.2024.126463_bb0335","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-bioeng-110220-031722","article-title":"Current developments and challenges of mRNA vaccines","volume":"24","author":"Chen","year":"2022","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.vaccine.2024.126463_bb0340","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","article-title":"The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case","volume":"112","author":"Oude Blenke","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2024.126463_bb0345","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine breakthrough infections with SARS-CoV-2 variants","volume":"384","author":"Hacisuleyman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126463_bb0350","doi-asserted-by":"crossref","first-page":"11692","DOI":"10.1128\/JVI.02018-15","article-title":"Virus-like particle vaccine containing the F protein of respiratory syncytial virus confers protection without pulmonary disease by modulating specific subsets of dendritic cells and effector T cells","volume":"89","author":"Kim","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0355","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/v16020316","article-title":"The influenza a virus replication cycle: a comprehensive review","volume":"16","author":"Carter","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.126463_bb0360","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1128\/JVI.74.14.6538-6545.2000","article-title":"Analysis of the transmembrane domain of influenza virus neuraminidase, a type II transmembrane glycoprotein, for apical sorting and raft association","volume":"74","author":"Barman","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0365","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/370606","article-title":"Association of Influenza Virus Proteins with membrane rafts","volume":"2011","author":"Veit","year":"2011","journal-title":"Adv Virol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0370","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/42408","article-title":"Functional rafts in cell membranes","volume":"387","author":"Simons","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.126463_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.devcel.2021.09.016","article-title":"S-acylation controls SARS-CoV-2 membrane lipid organization and enhances infectivity","volume":"56","author":"Mesquita","year":"2021","journal-title":"Dev Cell"},{"key":"10.1016\/j.vaccine.2024.126463_bb0380","article-title":"A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza a virus. Science","volume":"9","author":"Wang","year":"2023","journal-title":"Advances"},{"key":"10.1016\/j.vaccine.2024.126463_bb0385","first-page":"10","article-title":"Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses","author":"Bommireddy","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2024.126463_bb0390","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/pathogens10101291","article-title":"Neuraminidase in virus-like particles contributes to the protection against high dose of avian influenza virus challenge infection","volume":"10","author":"Kang","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2024.126463_bb0395","article-title":"Different immunity elicited by recombinant H5N1 hemagglutinin proteins containing Pauci-mannose, high-mannose, or complex type N-Glycans","volume":"8","author":"Lin","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2024.126463_bb0400","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/mBio.02556-14","article-title":"Vaccination with Adjuvanted recombinant neuraminidase induces broad heterologous, but not Heterosubtypic, cross-protection against influenza virus infection in mice","volume":"6","author":"Wohlbold","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2024.126463_bb0405","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1128\/jvi.67.10.5721-5723.1993","article-title":"Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition","volume":"67","author":"Johansson","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0410","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1073\/pnas.84.19.6869","article-title":"Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza a virus surface glycoproteins","volume":"84","author":"Johansson","year":"1987","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2024.126463_bb0415","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.4049\/jimmunol.138.9.3010","article-title":"Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees","volume":"138","author":"Kilbourne","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0420","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3390\/vaccines8030409","article-title":"Influenza neuraminidase: a neglected protein and its potential for a better influenza vaccine","volume":"8","author":"Giurgea","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2024.126463_bb0425","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.vaccine.2009.12.041","article-title":"A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects","volume":"28","author":"Cate","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126463_bb0430","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/infdis\/jir711","article-title":"A vero cell\u2013derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies","volume":"205","author":"Fritz","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126463_bb0435","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1006\/viro.2001.0992","article-title":"Viral neuraminidase treatment of dendritic cells enhances antigen-specific CD8+ T cell proliferation, but does not account for the CD4+ T cell Independence of the CD8+ T cell response during influenza virus infection","volume":"286","author":"Oh","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.126463_bb0440","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01006-18","article-title":"Neuraminidase-inhibiting antibody titers correlate with protection from heterologous influenza virus strains of the same neuraminidase subtype","volume":"92","author":"Walz","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0445","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12979-023-00344-w","article-title":"Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice","volume":"20","author":"Park","year":"2023","journal-title":"Immunity Ageing"},{"key":"10.1016\/j.vaccine.2024.126463_bb0450","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jip.2011.05.004","article-title":"Large-scale production and purification of VLP-based vaccines","volume":"107","author":"Vicente","year":"2011","journal-title":"J Invertebr Pathol"},{"key":"10.1016\/j.vaccine.2024.126463_bb0455","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/v15020392","article-title":"Respiratory viruses and virus-like particle vaccine development: how far have we advanced?","volume":"15","author":"Chu","year":"2023","journal-title":"Viruses"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24011459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24011459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T13:44:15Z","timestamp":1741873455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24011459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":91,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0264410X24011459"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126463","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 spike-based virus-like particles incorporate influenza H1\/N1 antigens and induce dual immunity in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126463"}}